Asset profile
Budesonide · Pulmicort
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Asthma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 1 direct rival (same mechanism and indication), 1 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Budesonide (Pulmicort): this drug | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
December 2026 (8)
Phase 2Multiple Myeloma, Plasma Cell LeukemiaRecruiting
Est. primary completion 2026-12 · NCT05405387 · CT.gov ↗
What to watch
Phase 3Eosinophilic EsophagitisActive not recruiting
Est. primary completion 2026-12 · NCT06596252 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2026-12 · NCT04314375 · CT.gov ↗
What to watch
Phase 2Radiation PneumonitisRecruiting
Est. primary completion 2026-12-01 · NCT03803787 · CT.gov ↗
What to watch
Phase 1/2Intubation ComplicationActive not recruiting
Est. primary completion 2026-12-30 · NCT03250975 · CT.gov ↗
What to watch
Phase 2Nasal ObstructionRecruiting
Est. primary completion 2026-12-30 · NCT06830109 · CT.gov ↗
What to watch
Phase 4Glomerulonephritis, IGA, Probiotics, BudesonideNot yet recruiting
Est. primary completion 2026-12-31 · NCT06528015 · CT.gov ↗
What to watch
Early phase / not applicableRecessive Dystrophic Epidermolysis Bullosa, Dysphagia, Esophageal StenosisNot yet recruiting
Est. primary completion 2026-12-31 · NCT07684105 · CT.gov ↗
What to watch
2027 (15)
April 2027 (1)
Phase 4AsthmaNot yet recruiting
Est. primary completion 2027-04-01 · NCT06568445 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Chronic Obstructive Pulmonary Disease, HyperinflationRecruiting
Est. primary completion 2027-05-31 · NCT07073950 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2AsthmaActive not recruiting
Est. primary completion 2027-06-21 · NCT06676319 · CT.gov ↗
What to watch
Phase 3AsthmaNot yet recruiting
Est. primary completion 2027-06-30 · NCT06895460 · CT.gov ↗
What to watch
Early phase / not applicableAllergic Rhinitis (Disorder), Electroacupuncture, Microneedle KnifeRecruiting
Est. primary completion 2027-06-30 · NCT06890260 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicablePost-acute Sequelae of SARS-COV-2 InfectionNot yet recruiting
Est. primary completion 2027-07 · NCT06597682 · CT.gov ↗
What to watch
September 2027 (2)
December 2027 (6)
Phase 1Eosinophilic Esophagitis (EoE)Enrolling by invitation
Est. primary completion 2027-12 · NCT07358234 · CT.gov ↗
What to watch
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2027-12 · NCT06334575 · CT.gov ↗
What to watch
Phase 3COPD (Chronic Obstructive Pulmonary Disease)Recruiting
Est. primary completion 2027-12-03 · NCT06283966 · CT.gov ↗
What to watch
Phase 3Chronic Rhinosinusitis (CRS)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07383402 · CT.gov ↗
What to watch
Phase 3Engraftment SyndromeRecruiting
Est. primary completion 2027-12-30 · NCT05509933 · CT.gov ↗
What to watch
Phase 2/3Crohn Disease (CD)Enrolling by invitation
Est. primary completion 2027-12-31 · NCT06719622 · CT.gov ↗
What to watch
2028 (5)
February 2028 (2)
April 2028 (1)
October 2028 (1)
Phase 4Sinus Infection, Acute SinusitisRecruiting
Est. primary completion 2028-10 · NCT06076304 · CT.gov ↗
What to watch
December 2028 (1)
2029 (5)
March 2029 (1)
Phase 1/2Invasive Mechanical Ventilation, Severe Respiratory Distress SyndromeNot yet recruiting
Est. primary completion 2029-03 · NCT06855043 · CT.gov ↗
What to watch
May 2029 (1)
Early phase / not applicableEsophageal StrictureNot yet recruiting
Est. primary completion 2029-05-01 · NCT07560462 · CT.gov ↗
What to watch
June 2029 (1)
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2029-06 · NCT05976802 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA GlomerulonephritisRecruiting
Est. primary completion 2029-08 · NCT06676384 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Pneumonitis, Immune-related Adverse EventRecruiting
Est. primary completion 2029-12-01 · NCT06860542 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.